Eli Lilly Zepbound Results - Search News

News

Zepbound beats Wegovy for weight loss

The Wall Street Journal on MSN · 2d

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

Seeking Alpha on MSN · 2d

Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( NVO) Wegovy (semaglutide) in a Phase 3b head-to-head trial.

Quartz on MSN · 2d

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.

Hosted on MSN3d

Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase ...

13d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results